Vaxxinit - Model UB-311 (Aß) - Neurodegeneration

Targets toxic forms of aggregated Aβ in the brain to fight Alzheimer’s. Phase 1, Phase 2a and Phase 2a LTE trials have shown UB-311 to be well tolerated in early AD subjects over three years of repeat dosing, with a safety profile comparable to placebo, with no cases of amyloid-related imaging abnormalities-edema (“ARIA-E”) in the main study. Highly immunogenic with a high responder rate and antibodies that bind to the desired target. The FDA has granted UB-311 Fast Track Designation.